AbbVie Inc. (ABBV)
Pharmaceutical Preparations · market cap $468.2B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
- 2026-12-15 (est.)Phase 2 · ABBV-400imp 7/10
- 2026-12-15 (est.)Phase 3 · Lutikizumabimp 9/10
- 2026-12-30 (est.)Phase 2 · Venetoclaximp 7/10
- 2027-01-01 (est.)Phase 2 · Liposomal daunorubicin and cytarabineimp 7/10
- 2027-01-15 (est.)Phase 3 · Livmoniplimabimp 9/10
- 2027-02-01 (est.)Phase 2 · Telisotuzumab vedotinimp 7/10
- 2027-02-15 (est.)Phase 2 · Lutikizumabimp 7/10
- 2027-02-28 (est.)Phase 2 · Venetoclaximp 7/10
| Asset | Phase | Indication |
|---|---|---|
| AGN-242428 | Phase 2 | Dry Eye Disease |
| ABBV-8E12 | Phase 2 | Alzheimer's Disease |
| Erwinia asparaginase | Phase 2 | Refractory Acute Lymphoblastic Leukemia |
| Risankizumab On-Body Injector (OBI) | Phase 3 | Crohn's Disease |
| BIIB019 (Daclizumab High Yield Process) | Phase 2 | Relapsing-Remitting Multiple Sclerosis |
| Intrathecal Triples | Phase 2 | Refractory Acute Lymphoblastic Leukemia |
| Bimatoprost (SR) | Phase 3 | Open-Angle Glaucoma |
| APG777 | Phase 2 | Atopic Dermatitis |
| Brimonidine tartrate ophthalmic solution eye drops | Phase 2 | Recurrent Ovarian Cancer |
| Thioguanine | Phase 2 | T-cell Acute Lymphoblastic Leukemia |
| ABBV-8736 | Phase 2 | Crohn's Disease |
| Adalimumab-800CW | Phase 2 | IBD |
| Pancreatic Enzyme | Phase 2 | Short Bowel Syndrome |
| Prednisolone acetate ophthalmic suspension eye drops | Phase 2 | Recurrent Ovarian Cancer |
| Calaspargase pegol | Phase 2 | T-cell Acute Lymphoblastic Leukemia |
| Recombinant Granulocyte Colony-Stimulating Factor | Phase 2 | Acute Biphenotypic Leukemia |
| Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) | Phase 2 | T-cell Acute Lymphoblastic Leukemia |
| Trosunilimab | Phase 2 | Crohn's Disease |
| Pegylated interferon (pegIFN) | Phase 2 | Chronic Hepatitis C |
| etanercept | Phase 3 | Moderate to Severe Plaque Psoriasis |
Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for ABBV (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
